NCT03276065 is a NA clinical trial of Laser depilation in Pilonidal Disease, sponsored by Nationwide Children's Hospital.

Who is sponsoring NCT03276065?

NCT03276065 is sponsored by Nationwide Children's Hospital.

What drugs are being tested in NCT03276065?

Interventions in NCT03276065: Laser depilation, Standard of care hair depilation.

What condition does NCT03276065 study?

NCT03276065 studies Pilonidal Disease.

Is NCT03276065 still recruiting?

NCT03276065 is currently status unknown. Last updated 25 July 2022.

Last reviewed 2022-07-25 · How we verify

NCT03276065

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of Laser Hair Removal in Pilonidal Disease

Status unknown NA Last updated 25 July 2022

What this trial tests

NA trial testing Laser depilation in Pilonidal Disease in 302 participants. Status unknown.

Timeline

5 September 2017

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Nationwide Children's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	302
Start date	5 September 2017
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across United States

Drugs / interventions tested

Laser depilation
Standard of care hair depilation

Conditions studied

Pilonidal Disease — all drugs for Pilonidal Disease →

Sponsor

Nationwide Children's Hospital

Who can join

Adults 11 to 21, any sex, with Pilonidal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pilonidal disease is a common painful condition that affects 26 per 100,000 people with an incidence of 1.1% in the young male population. Recurrence rates of pilonidal disease after initial incision and drainage and after resection have been reported to be 16% and 11% respectively. Furthermore, wound issues after resection with primary closure have been reported to be as high as 30%. In several retrospective studies and small prospective studies, laser hair removal has shown promise as an adjunct therapy to decrease recurrent infections and decrease the need for repeat surgery in adults and older adolescents. We are performing a randomized control trial of laser hair depilation plus chemical/mechanical depilation to examine outcomes related to recurrence of pilonidal disease.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Laser Epilation as an Adjunct to Standard Care in Reducing Pilonidal Disease Recurrence in Adolescents and Young Adults: A Randomized Clinical Trial.
Minneci PC, Gil LA, Cooper JN, Asti L, et al · · 2024 · cited 20× · PMID 37938854 · DOI 10.1001/jamasurg.2023.5526
Laser hair depilation for the prevention of disease recurrence in adolescents and young adults with pilonidal disease: study protocol for a randomized controlled trial.
Minneci PC, Halleran DR, Lawrence AE, Fischer BA, et al · · 2018 · cited 10× · PMID 30382903 · DOI 10.1186/s13063-018-2987-7
Heterogeneity of Treatment Effects of Laser Epilation on Pilonidal Disease Recurrence: A Randomized Clinical Trial.
Bergus KC, Lutz C, Cooper J, Asti L, et al · · 2024 · cited 3× · PMID 39310334 · DOI 10.1097/as9.0000000000000488
Comparing Hair Removal Treatments for Adolescents and Young Adults with Pilonidal Disease
Minneci PC. · · 2024 · PMID 42118898

Verify or expand the search:

Other trials of Laser depilation

Trials testing the same drug.

NCT02778152 — Pilot Study of Laser Hair Depilation for Pilonidal Disease · NA · completed

Other recruiting trials for Pilonidal Disease

Currently open trials in the same condition.

NCT07321704 — Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous F · NA · recruiting
NCT06406621 — Pilot Trial Assessing the Effectiveness of Laser Hair Depilation on Pilonidal Disease Recurrence in Patients With Darker · NA · recruiting
NCT06286397 — Topical Anti-Androgens in Pilonidal Sinus Disease · Phase 2 · recruiting
NCT06391307 — The Role of Mesenchymal Stem Cell and Exosome in Treating Pilonidal Sinus Disease in Children · NA · recruiting
NCT03772873 — MIPE for Pilonidal Disease · active not recruiting

Other Nationwide Children's Hospital trials

Trials by the same sponsor.

NCT07435792 — TetraGraph to Evaluate Onset and Recovery Times of Rocuronium · NA · not yet recruiting
NCT07026942 — Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML · Phase 1, PHASE2 · not yet recruiting
NCT06795126 — Little NIRVANA for Pediatric Pain and Anxiety · NA · enrolling by invitation
NCT06854991 — Healthy Children and Virtual Reality Mediation of Simulated Pain · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03276065 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nationwide Children's Hospital
Last refreshed: 25 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03276065.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing